Results 21 to 30 of about 8,266,387 (310)
Table_1_Therapeutic exercise interventions in pediatric survivors of brain cancer and other solid tumors: A scoping review.pdf [PDF]
, 2022 BackgroundImproved survival rates for children with solid tumors presents an ongoing challenge of how to maximize quality of survivorship and effectively manage the short- and long-term complications of disease and treatment.
Sandler, Carolina X +14 more
core +1 more source
Genome Medicine, 2021 Background Malignant pleural mesothelioma (MPM) is a heterogeneous cancer. Better knowledge of molecular and cellular intra-tumor heterogeneity throughout the thoracic cavity is required to develop efficient therapies.
Clément Meiller +21 more
doaj +1 more source
The Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors
Chemical Reviews, 2021 Nanomaterial (NM) delivery to solid tumors has been the focus of intense research for over a decade. Classically, scientists have tried to improve NM delivery by employing passive or active targeting strategies, making use of the so-called enhanced ...
Mukaddes Izci +3 more
semanticscholar +1 more source
Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST).
Annals of Oncology, 2023 Current evaluation of treatment response in solid tumors depends on dynamic changes in tumor diameters as measured by imaging. However, these changes can only be detected when there are enough macroscopic changes in tumor volume, which limits the ...
M. Gouda +11 more
semanticscholar +1 more source
Principles of Nanoparticle Delivery to Solid Tumors
BME Frontiers, 2023 The effective treatment of patients with cancer hinges on the delivery of therapeutics to a tumor site. Nanoparticles provide an essential transport system.
Warren Chan
semanticscholar +1 more source
Nature Medicine, 2022 Oncogenic RET fusions occur in diverse cancers. Pralsetinib is a potent, selective inhibitor of RET receptor tyrosine kinase. ARROW (NCT03037385, ongoing) was designed to evaluate pralsetinib efficacy and safety in patients with advanced RET-altered ...
V. Subbiah +18 more
semanticscholar +1 more source
Journal for ImmunoTherapy of Cancer, 2019 Growing evidence suggests a clear role of the host immune system in HER2+ breast cancer. In addition, HER2+ breast cancer is generally considered more immunogenic than hormone receptor-positive (HR+)/HER2-, and specific molecular HER2+ subgroups (e.g ...
Gaia Griguolo +4 more
doaj +1 more source
NK cells and solid tumors: therapeutic potential and persisting obstacles
Molecular Cancer, 2022 Natural killer (NK) cells, which are innate lymphocytes endowed with potent cytotoxic activity, have recently attracted attention as potential anticancer therapeutics.
L. Tông +5 more
semanticscholar +1 more source
CAR T cells in solid tumors: challenges and opportunities
Stem cell research & therapeutics, 2021 CARs are simulated receptors containing an extracellular single-chain variable fragment (scFv), a transmembrane domain, as well as an intracellular region of immunoreceptor tyrosine-based activation motifs (ITAMs) in association with a co-stimulatory ...
F. Marofi +14 more
semanticscholar +1 more source
Numerical simulation of solid tumor blood perfusion and drug delivery during the “vascular normalization window” with antiangiogenic therapy [PDF]
, 2011 This Article is provided by the Brunel Open Access Publishing Fund - Copyright @ 2011 Hindawi PublishingTo investigate the influence of vascular normalization on solid tumor blood perfusion and drug delivery, we used the generated blood vessel network ...
Long, Q +13 more
core +1 more source